Organon & Co. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Organon & Co. (OGN) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$793.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-24
- Organon & Co. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$793.00M.
- Organon & Co. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$479.00M.
- Organon & Co. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$554.00M.
- Organon & Co. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$451.00M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$793.00M 10-K · filed 2026-02-24 |
| 2024-12-31 | -$479.00M 10-K · filed 2026-02-24 |
| 2023-12-31 | -$554.00M 10-K · filed 2026-02-24 |
| 2022-12-31 | -$451.00M 10-K/A · filed 2025-11-10 |
| 2021-12-31 | -$96.00M 10-K · filed 2024-02-26 |
| 2020-12-31 | $532.00M 10-K · filed 2023-02-27 |
| 2019-12-31 | $564.00M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |